Enzolytics Inc (ENZC)

[God_Father]

MASSIVE UPDATE!! Allow me to dissect this for you the significance of this PR.

https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-2020-Year-End-Update?id=284809

1) The Company has also negotiated a debt exchange whereby most of the existing convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for the next two years. We believe this step, along with the reorganization under Section 251 G that was initiated prior to the closing of the combination agreement, will significantly enhance the equity position of the Company.

First and foremost, in November the Company mentioned that conversion had subsided for 30 days. NOW, we know why. The company has negotiated MOST of their convertible debt. This confirms that dilution has virtually stopped. Considering that AS hasn't increased, we know this is the case. They are pushing it down 2-years. This is HUGE as it takes convincing debtors that we have significant value to offer, and they accepted.

2) In addition to these successes, we have been very successful in raising necessary funding to execute our plans. Our initial $500,000 raise is being followed with $1 million being funded in the next 30 days, and additional investment is being made into the Company by officers of the Company, bringing the total raised since the signing of the non-binding letter of intent to $1.7 million.

The Company has even MORE funds now to continue operations. $1.7MM to be exact and does not even include NIH / NSF application funding that is expected here. Considering that even their own officers are investing tells me the level of CONFIDENCE we have going forward. I wouldn't be surprised in an upcoming filing to see that there is insider buying and folks in the company buying up shares. HUUUGEE!!!


3) Since the signing of the original non-binding letter of intent, the Company has filed two annual reports and eight quarterly reports, with the required OTC alternative reporting supplemental information, and will soon be filing the last quarterly filing and opinion letter with OTC Markets needed to bring the Company to a current status.

This is a NO-BRAINER, Company IS absolutely going to be OTC CURRENT next month. We are one filing away.

4) The Company is an OTC Market Alternative Standard Reporting entity and is not fully reporting. All of the information that would be required in SEC reporting is included in our Supplemental Information filings and is current. Currently, the Company has requested proposals from several PCAOB accounting firms to provide quotes for Audits of the Company's current and prior year Financial Statements in order to become fully reporting. Bids were requested to be provided by mid-January, and the Company anticipates making a decision by the end of January 2021.

THIS IS NEW DEVELOPMENT. The last filing to bring the Company to Current status is for "Alternative Standard Reporting". They now mention that they are going to FULLY AUDIT financials to be "SEC REPORTING". THIS IS HUUUUUGEEE!!!!! Why you may ask? Because its needed to UPLIST. i.e. OTCQB requires U.S. companies to have audited annual financials by a PCAOB auditor. WE ARE LIKELY GOING TO UPLIST TO A HIGHER TIER!!!!!! OTCQB coming up

5) In addition to those primary targets on these viruses already known to us, we have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.

Confirmation that we are collaborating with other Companies, likely at A&M where now AI will be used for our mAbs. Name me a few companies with this sort of capability and I will tell you of potential partnerships that are going to take place. More DD on this to follow.

6) On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as well as multiple anti-CoronaVirus monoclonal antibodies for use as a therapeutic against the SARS-CoV-2 virus.

If you weren't aware of this, for the love of God. Do some DD on this company. HUUUUGE!!!!